CUPERTINO, Calif., Aug. 3, 2023
/PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX), a
biopharmaceutical company committed to transforming the treatment
of acute organ injury and chronic liver diseases by advancing novel
and potentially lifesaving therapies based on its endogenous
epigenetic regulator program, today announced that the company will
report its financial results for the three months ended
June 30, 2023 on Wednesday, August 9, 2023. Management will
also host a conference call with investors to discuss financial
results and provide a corporate update at 4:30 pm Eastern Time. Details for the call
is as follows:
Wednesday, August 9 @ 4:30pm Eastern
Time / 1:30pm Pacific Time
Toll Free: 1-877-407-0784
International: 1-201-689-8560
Conference ID: 13740526
Call me™: click here
Participants can use guest dial-in numbers above to reach an
operator or they can click the Call me™ link for instant
telephone access to the event (dial-out). The Call me™ link
will be made active 15 minutes prior to the scheduled start
time.
Webcast:
https://viavid.webcasts.com/starthere.jsp?ei=1628151&tp_key=ba103a2a9b
About DURECT Corporation
DURECT is a biopharmaceutical
company committed to transforming the treatment of acute organ
injury and chronic liver diseases by advancing novel and
potentially lifesaving therapies based on its endogenous epigenetic
regulator program. Larsucosterol (also known as DUR-928), DURECT's
lead drug candidate, binds to and inhibits the activity of DNA
methyltransferases (DNMTs), epigenetic enzymes which are elevated
and associated with hypermethylation found in alcohol-associated
hepatitis (AH) patients. Larsucosterol is in clinical development
for the potential treatment of AH, for which FDA has granted a Fast
Track Designation; non-alcoholic steatohepatitis (NASH) is also
being explored. In addition, POSIMIR® (bupivacaine
solution) for infiltration use, a non-opioid analgesic utilizing
the innovative SABER® platform technology, is
FDA-approved and has been exclusively licensed to Innocoll
Pharmaceuticals for commercialization in the United States. For more information about
DURECT, please visit www.durect.com and follow us on Twitter
https://twitter.com/DURECTCorp.
DURECT Forward-Looking Statements
This press release
contains forward-looking statements, including statements made
pursuant to the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995, relating to: our plans to report
topline data in the fourth quarter of 2023, the potential FDA
approval of larsucosterol for the treatment of AH, the ability of a
positive outcome in the AHFIRM trial to support a New Drug
Application filing, our plans to commercialize larsucosterol if
approved, the commercialization of POSIMIR by Innocoll, the
potential to develop larsucosterol for AH, NASH or other
indications, and the potential benefits, if any, of our product
candidates. Actual results may differ materially from those
contained in the forward-looking statements contained in this press
release, and reported results should not be considered as an
indication of future performance. The potential risks and
uncertainties that could cause actual results to differ from those
projected include, among other things, the risks that the AHFIRM
trial takes longer to complete than anticipated, the risk that
ongoing and future clinical trials of larsucosterol do not confirm
the results from earlier clinical or pre-clinical trials, or do not
demonstrate the safety or efficacy of larsucosterol in a
statistically significant manner, the risk that the FDA or other
government agencies may require additional clinical trials for
larsucosterol before approving it for the treatment of AH even if
the results of the AHFIRM trial are successful, risks that Innocoll
may not commercialize POSIMIR successfully, and risks related to
the sufficiency of our cash resources, our anticipated capital
requirements and capital expenditures, our need or desire for
additional financing, our ability to obtain capital to fund our
operations and expenses and our ability to continue to operate as a
going concern. Further information regarding these and other risks
is included in DURECT's most recent Securities and Exchange
Commission (SEC) filings, including its annual report on Form 10-K
for the year ended December 31, 2022
and quarterly report on Form 10-Q for the quarter ended
June 30, 2023 when filed under the
heading "Risk Factors." These reports are available on our
website www.durect.comunder the "Investors" tab and on the SEC's
website at www.sec.gov. All information provided in this press
release and in the attachments is based on information available to
DURECT as of the date hereof, and DURECT assumes no obligation to
update this information as a result of future events or
developments, except as required by law.
NOTE: POSIMIR® is a trademark of Innocoll
Pharmaceuticals, Ltd. in the U.S. and a trademark of DURECT
Corporation outside of the U.S. SABER® is a trademark of
DURECT Corporation. Other referenced trademarks belong to their
respective owners. Larsucosterol (DUR-928) is an investigational
drug candidate under development and has not been approved for
commercialization by the U.S. Food and Drug Administration or other
health authorities for any indication.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/durect-corporation-to-announce-second-quarter-2023-financial-results-and-provide-a-business-update-301893056.html
SOURCE DURECT Corporation